Key Takeaways

  • Cochlear's A$118 share price is not the result of a split or capital reconstruction; it follows a de-rating of close to 60 per cent after the company cut FY26 underlying net profit guidance from A$435-460 million to A$290-330 million on 22 April 2026.
  • No confirmed company-specific catalyst was identified for the 28 July gain; health care outperformed the wider market that morning, and the stock has been recovering from a A$88.74 low since late April.
  • FY26 results are ordinarily released mid-August and will test whether April's second-half assumptions held and what FY27 guidance looks like.

Cochlear Limited (ASX: COH) was among the firmer large caps on Tuesday 28 July, showing the hearing implant maker up 3.40 per cent at A$118.39.

The price level demands explanation. Cochlear traded above A$300 within the past year; providers put its 52-week range at A$88.74 to A$319.56. There has been no share split, bonus issue or capital reconstruction. What occurred was a de-rating near 60 per cent, triggered by an April profit downgrade among the most severe in the company's listed history.

No confirmed catalyst behind Tuesday's move

No ASX announcement, regulatory decision or company statement explaining a 3.4 per cent move on 28 July has been identified. No definitive company-specific catalyst was found.

Less satisfying explanations remain plausible. Health care outperformed the broader index that morning, consistent with rotation into defensive earnings; Cochlear is a volatile participant in that trade. It has also been recovering, from a low near A$88.74 to above A$120 by late June. Moves of this size in a halved share price often reflect positioning, short covering and thin liquidity rather than fresh information. The 3.40 per cent figure is itself provisional, drawn from a 20-minute-delayed mid-session feed; the closing print has not been verified.

Osia 3 clearance is the most recent development

The latest substantive news is product, not financial. On 13 July 2026 Cochlear introduced the Osia 3 Sound Processor, which it calls the first fully rechargeable active bone conduction processor, offering 30 hours of battery life and Auracast streaming. The company said it had FDA clearance and would reach the US in the northern autumn. Existing Osia recipients can upgrade regardless of implant model, useful commercially but no remedy for the volume shortfall behind the downgrade.

The downgrade that reset expectations

Cochlear entered FY26 guiding to underlying net profit of A$435 million to A$460 million. The 13 February 2026 half-year result showed sales revenue of A$1,176.0 million, up 1 per cent (down 2 per cent in constant currency), underlying net profit of A$194.8 million, down 9 per cent, and statutory profit of A$161.5 million, down 21 per cent. Gross margin slipped to 73 per cent from 75 per cent, and guidance was narrowed to the range's lower end.

The heavier blow landed on 22 April, when guidance was cut to A$290 million to A$330 million. Cochlear cited softer developed market implant sales since January, up to A$10 million from Middle East receivables and cancellations, roughly A$20 million of gross margin pressure from weaker overhead recovery, A$18 million to A$25 million of restructuring charges, and about A$25 million of after-tax currency headwind. The shares fell around 39 per cent to about A$101.60.

The detail troubled as much as the number: US volumes fell in March on weaker hearing aid referrals, while European surgery was constrained by hospital capacity and lengthening waiting lists in Britain and Germany.

What the business actually sells

Revenue splits three ways. In FY25, to 30 June 2025, sales revenue reached A$2,355.8 million, up 4 per cent. Cochlear implants contributed A$1,470.2 million on 53,968 units, up 11 and 12 per cent respectively. Services, processor upgrades and accessories sold to the existing base, contributed A$609.2 million, down 9 per cent. Acoustics, the Osia and Baha bone conduction ranges, contributed A$276.4 million, up 8 per cent.

Underlying net profit was A$391.6 million, up 1 per cent; statutory net profit A$388.9 million, up 9 per cent. Gross margin was 74 per cent, research and development absorbed A$291.5 million or 12 per cent of sales, and dividends totalled A$4.30 per share, a 72 per cent payout of underlying profit.

Where growth is meant to come from

Three drivers underpin the recovery case. The first is the Nucleus Nexa System, FDA-approved and announced in July 2025, the first cochlear implant whose firmware updates without further surgery. By December 2025 about 80 per cent of units sold were Nexa, market share improving once hospital contracting completed, a process that ran longer than expected and cost first-half growth.

The second is the upgrade cycle: retiring the Nucleus 7 in the United States and launching the Kanso 3 and Osia 3 turns an installed base into recurring revenue, yet services revenue fell in FY25 and grew only 2 per cent in the December half. The third is emerging market volume, up more than 15 per cent. The catch is price.

A dominant share, and a pricing problem in China

Morningstar estimates Cochlear holds roughly 60 per cent of the global cochlear implant market, competing mainly with Sonova's Advanced Bionics, MED-EL and China's Nurotron. Sonova puts worldwide market growth near 8 per cent a year against substantial untreated demand.

China shows both sides. In December 2024 the National Healthcare Security Administration put cochlear implants through centralised volume-based procurement, cutting prices from above 200,000 yuan to about 50,000 yuan across 11,000 sets from five bidders, effective March 2025; Advanced Bionics was among them. Cochlear has since reported emerging market unit growth outstripping revenue growth on mix shift to lower tiers, plus premium-tier reimbursement cuts in special access zones. Volume is arriving; margin is not.

Balance sheet, pipeline and execution

Cochlear remains in net cash, but the buffer is thinning: A$275.7 million at 30 June 2025, down A$237.9 million year on year, then A$172.7 million at 31 December 2025, a further A$103 million reduction. The company stays funded, research and development running at 12 to 13 per cent of sales. But a 72 per cent payout policy applied to a profit line guided roughly A$145 million lower mechanically shrinks the dividend and leaves less room for April's flagged restructuring.

Regulatory and clinical positioning is comparatively strong. Nexa and Osia 3 both hold FDA approval or clearance, and the Oticon Medical implant business bought from Demant, completed in May 2024, has been absorbed. The constraint is not technology or approval but surgical capacity, referral flow and payer willingness.

The risks that matter most

The central risk is that April's downgrade proves structural rather than cyclical. Weak US hearing aid referrals and lengthening European waiting lists are not conditions Cochlear controls, and neither responds quickly to a better implant. Currency remains live: revised guidance assumes AUD/USD at 71 cents and AUD/EUR at 61 cents, and further Australian dollar strength would erode it. A largely fixed manufacturing base also means volume shortfalls pass straight into gross margin.

Valuation after the de-rating

Prices and multiples change continuously; the figures here are point-in-time. Data provider stockanalysis.com listed Cochlear on a trailing price-earnings ratio near 22.9, a market capitalisation around A$7.9 billion and a consensus target from 16 analysts of about A$127. For a company that long commanded one of the ASX's highest earnings multiples, a low-twenties trailing multiple is a genuine reset. But it rests on FY25 earnings, and FY26 underlying profit is guided materially lower, so the multiple on guided FY26 profit is considerably higher. Buyers of this recovery are paying for FY27, not the year being reported.

August is the next real test

Cochlear's year ended 30 June and results are ordinarily released mid-August; FY25 came on 15 August 2025, though no FY26 date appeared on the investor site at the time of writing. It will test whether April's second-half assumptions held, whether Nexa adoption converted into units, and what FY27 guidance looks like.

The constructive case rests on a differentiated product cycle, a recovering upgrade stream and a reshaped cost base meeting an easier comparison. The bearish case is that developed market volumes are structurally slower than Cochlear's history assumed. Tuesday's move settles neither.